P&G Could Be Last Suitor Standing For Pfizer's Consumer Health Business
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
A spin-off still is an option for Pfizer, as is continuing to operate the unit as it currently does. But P&G's apparent interest and dearth of other OTC business buyers changes the outlook for both companies.